Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the popular weight-loss drug, Wegovy. The Danish pharmaceutical giant and Hims & ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

Hims & Hers (HIMS) is bringing access to its comprehensive weight loss program to the UK. After a detailed clinical ...

Hims & Hers Health Inc. HIMS shares are trading lower Tuesday after GoodRx Inc. GDRX announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, ...

Hims & Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept. 9, addressed to the ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.